First Trust Managed Municipal ETF (NASDAQ: FMB)

Ultime notizie per First Trust Managed Municipal ETF (NASDAQ:FMB)

First Trust Managed Municipal ETF

Under normal market conditions, the fund seeks to achieve its investment objectives by investing at least 80% of its net assets (including investment borrowings) in municipal debt securities that pay interest that is exempt from regular federal income taxes.

First Mid Bancshares, Inc. - Common Stock

First Mid Bancshares Inc

FRMRS&MER BK LONG BCH CAL by Farmers & Merchants Bank of Long Beach (CA)

Farmers & Merchants Bank of Long Beach

F & M Bank Corp

FRMRS&MER BNCSHS IOWA by Farmers & Merchants Bancshares, Inc.

Farmers and Merchants Bancshares Inc

FAMOUS BRANDS UNSP/ADR by Famous Brands Ltd

Famous Brands Ltd

FULL MOTION BEVERAGE INC by Full Motion Beverage, Inc.

Full Motion Beverage Inc

<p>Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) has been analyzed by 19 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Atlassian, presenting an average target of $242.58, a high estimate of $300.00, and a low estimate of $200.00. This current average has increased by 16.07% from the previous average price target of $209.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731603659_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Atlassian. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$255.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$250.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$224.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Atlassian. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Atlassian compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Atlassian's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Atlassian's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TEAM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Atlassian analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Atlassian</h2>
<p>Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.</p>
<h3>Breaking Down Atlassian's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Atlassian's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>21.48%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Atlassian's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-10.42%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Atlassian's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-12.01%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Atlassian's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.43%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Atlassian's debt-to-equity ratio surpasses industry norms, standing at <strong>1.21</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

TEAM

A Closer Look at 19 Analyst Recommendations For Atlassian

<p>During the last three months, 4 analysts shared their evaluations of Four Corners Prop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $30.5, a high estimate of $33.00, and a low estimate of $28.00. This current average has increased by 12.96% from the previous average price target of $27.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731603649_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Four Corners Prop. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$33.00</td>
<td>-</td>
</tr>
<tr>
<td>Heather Bellini</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Four Corners Prop. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Four Corners Prop compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Four Corners Prop's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FCPT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Four Corners Prop analyst ratings.</strong></a></p>
<h2>Delving into Four Corners Prop's Background</h2>
<p>Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.</p>
<h3>Financial Insights: Four Corners Prop</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Four Corners Prop's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>3.01%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Four Corners Prop's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>38.3%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Four Corners Prop's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.96%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.01%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Four Corners Prop's debt-to-equity ratio is below the industry average. With a ratio of <b>0.84</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FCPT

What Analysts Are Saying About Four Corners Prop Stock

<p>Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $128.0, along with a high estimate of $151.00 and a low estimate of $88.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.58%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731603642_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$88.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Blueprint Medicines's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blueprint Medicines's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Blueprint Medicines analyst ratings.</strong></a></p>
<h2>Discovering Blueprint Medicines: A Closer Look</h2>
<p>Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.</p>
<h3>Financial Milestones: Blueprint Medicines's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Blueprint Medicines displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>126.61%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Blueprint Medicines's net margin is impressive, surpassing industry averages. With a net margin of <strong>-43.9%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Blueprint Medicines's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-17.77%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Blueprint Medicines's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-4.68%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Blueprint Medicines's debt-to-equity ratio surpasses industry norms, standing at <strong>1.51</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BPMC

Key Takeaways From Blueprint Medicines Analyst Ratings

<p>In the preceding three months, 4 analysts have released ratings for 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $37.5, a high estimate of $39.00, and a low estimate of $36.00. A 2.6% drop is evident in the current average compared to the previous average price target of $38.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731603635_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive 4D Molecular Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$39.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mani Foroohar</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Caufield</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of 4D Molecular Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into 4D Molecular Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FDMT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on 4D Molecular Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering 4D Molecular Therapeutics: A Closer Look</h2>
<p>4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.</p>
<h3>A Deep Dive into 4D Molecular Therapeutics's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Challenges:</strong> 4D Molecular Therapeutics's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-97.91%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> 4D Molecular Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-699060.0%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> 4D Molecular Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.88%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> 4D Molecular Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-5.59%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FDMT

Analyst Expectations For 4D Molecular Therapeutics's Future

<p>Across the recent three months, 9 analysts have shared their insights on Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $188.11, a high estimate of $220.00, and a low estimate of $147.00. Highlighting a 1.51% decrease, the current average has fallen from the previous average price target of $191.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731603627_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Abercrombie &amp; Fitch's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandra Steiger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$147.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$208.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Abercrombie &amp; Fitch. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abercrombie &amp; Fitch compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Abercrombie &amp; Fitch's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Abercrombie &amp; Fitch's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ANF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Abercrombie &amp; Fitch analyst ratings.</strong></a></p>
<h2>Get to Know Abercrombie &amp; Fitch Better</h2>
<p>Abercrombie &amp; Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumers through its stores and websites, which include the Abercrombie &amp; Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.</p>
<h3>Abercrombie &amp; Fitch: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Abercrombie &amp; Fitch's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>21.24%</strong> as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>11.74%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Abercrombie &amp; Fitch's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>11.65%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Abercrombie &amp; Fitch's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>4.42%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Abercrombie &amp; Fitch's debt-to-equity ratio is below the industry average at <strong>0.74</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Abercrombie & Fitch: Insights From 9 Financial Analysts

<p><strong>Visa Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) shares are trading higher by 6.7% to $310.24 in November following <strong>Donald Trump's</strong> <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a> as investors anticipate that his economic policies could boost consumer spending and, consequently, transaction volumes—a core revenue driver for Visa.</p>
<p><strong>What To Know:</strong> Trump's proposed tax cuts aim to increase disposable income for individuals and corporations, potentially fueling higher consumer spending levels. For Visa, which earns fees from every transaction on its global payment network, an uptick in spending would directly translate into increased processing volume, bolstering revenue growth.</p>
<p>In addition to tax policies, Trump's focus on reducing regulations could benefit Visa's operations in financial technology and digital payments. As new payment technologies and financial products proliferate, less regulatory pressure may allow Visa to innovate and expand its payment solutions more freely, enhancing its market reach in the competitive fintech space.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a></strong></p>
<p>This flexibility could be crucial as Visa continues to invest in expanding its digital payment services and partnerships, particularly in emerging markets and with e-commerce providers.</p>
<p><strong>What Else:</strong> Additionally, Trump's pro-business policies and anticipated infrastructure investments could support overall economic growth, which would likely benefit Visa's large base of business clients by increasing both domestic and international spending. </p>
<p>While some concerns remain about Trump's potential trade policies, Visa's well-diversified global network positions it to capitalize on spending growth across both consumer and commercial sectors, strengthening investor confidence in Visa's growth trajectory post-election.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a></strong></p>
<h2 class="wp-block-heading">How To Buy V Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)'s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, V has a 52-week high of $312.44 and a 52-week low of $245.34.</p>


News

What's Going On With Visa Stock?

<p>B of A Securities  analyst Ronald Epstein   maintains BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) with a Buy and raises the price target from $115 to $160.</p>


Price Target

BWXT

B of A Securities Maintains Buy on BWX Technologies, Raises Price Target to $160

WIIM

DADA

Dada Nexus shares are trading lower. The company reported Q3 financial results.

ICAD

Icad shares are trading lower after the company reported worse-than-expected Q3 revenue results.

<p>B of A Securities  analyst Ronald Epstein   maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and raises the price target from $10 to $30.</p>


RKLB

B of A Securities Maintains Buy on Rocket Lab USA, Raises Price Target to $30

Trading Ideas

HTOO

Fusion Fuel Green Shares Halted On Circuit Breaker To The Upside, Stock Now Up 106.9%

<p>RBC Capital  analyst Sean Dodge   maintains OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) with a Outperform and lowers the price target from $14 to $7.</p>


OPRX

RBC Capital Maintains Outperform on OptimizeRx, Lowers Price Target to $7

GORV

Lazydays Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 112%

<p>B of A Securities  analyst Tal Liani   maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Buy and raises the price target from $60 to $72.</p>


CSCO

B of A Securities Maintains Buy on Cisco Systems, Raises Price Target to $72

ADAP

Adaptimmune Therapeutics shares are trading lower. The company reported Q3 financial results.

<p><a href="https://www.wsj.com/business/boeing-hires-northrop-executive-to-revamp-pentagon-projects-d64dab73?mod=latest_headlines">https://www.wsj.com/business/boeing-hires-northrop-executive-to-revamp-pentagon-projects-d64dab73?mod=latest_headlines</a></p>
<p><a href="https://www.wsj.com/market-data/quotes/BA">Boeing</a> has poached an executive from defense rival <a href="https://www.wsj.com/market-data/quotes/NOC">Northrop Grumman</a> to run its Phantom Works division, which oversees research efforts for its Pentagon business and is involved in bidding for U.S. government projects.</p>
<p>Colin Miler, a former Air Force commander who oversaw aeronautics engineering at Northrop, will take over the division, the jet maker told employees on Thursday. The Phantom Works division is also being combined into a single business unit. It currently is divided into separate organizations within Boeing's defense business.&nbsp;</p>


Management

'Boeing Hires Northrop Executive To Revamp Pentagon Projects; Aerospace Giant Has Been Losing Billions On Military Contracts' - WSJ

<p>RBC Capital  analyst Luca Issi   maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Outperform and lowers the price target from $40 to $39.</p>


RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Lowers Price Target to $39

<p>RBC Capital  analyst Ben Hendrix   reiterates Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) with a Outperform and maintains $136 price target.</p>


Reiteration

ADUS

RBC Capital Reiterates Outperform on Addus HomeCare, Maintains $136 Price Target

<p><strong>Nu Holdings Ltd.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) shares are trading lower Thursday after the company reported third-quarter financial results late Wednesday. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/11/41955291/warren-buffett-backed-bank-nu-holdings-posts-q3-results-eps-in-line-revenues-beat-estimates">what you need to know.</a></p>
<p><strong>What To Know:</strong> Nu Holdings, a Brazilian digital bank backed by <strong>Warren Buffett</strong>, posted earnings of 11 cents per share, matching analyst expectations, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a> Revenue for the quarter was $2.94 billion, beating the expected $2.85 billion. The company&#8217;s top-line results were up from $2.14 billion in the same period last year.</p>
<p>In terms of customer growth, Nu Holdings added 5.2 million customers, bringing its global customer base up to 109.7 million as of Sept. 30. Nu&#8217;s customer base grew 23% year-over-year. </p>
<p>The company&#8217;s Monthly Average Revenue per Active Customer (ARPAC) rose to $11 in the third quarter, while the cost to serve each customer remained low at 70 cents.</p>
<p>&#8220;Our third quarter 2024 underscores the strength of our business model, demonstrating top-line growth and sustained profitability,&#8221; said <strong>David Vélez</strong>, Nubank&#8217;s founder and CEO.</p>
<p>Following the report, multiple analysts <a href="https://www.benzinga.com/analyst-stock-ratings">adjusted price targets</a>. Susquehanna analyst <strong>James Friedman</strong> raised his price target from $16 to $18, maintaining a Positive rating on the stock. Similarly, Keybanc analyst <strong>Alex Markgraff</strong> raised his target from $15 to $17, keeping an Overweight rating. Goldman Sachs also maintained a Buy rating and raised its target from $17 to $19.</p>
<p><strong>NU Price Action: </strong>Nu Holdings shares were down 8.34% at $14.34 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14095323/NU-1024x542.png" alt="" class="wp-image-648145" style="width:407px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14095323/NU-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14095323/NU-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14095323/NU-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14095323/NU.png 1161w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/11/41975042/nice-beats-q3-estimates-on-strong-sales-raises-outlook">Nice Beats Q3 Estimates On Strong Sales, Raises Outlook</a></strong></li>
</ul>
<p><em>Image via Blog Nu Mexico</em>.</p>


Earnings

Movers

Nu Holdings Shares Are Trading Down Today: What's Going On?

CAPR

Capricor Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $25 to $30.

Comments

First Trust Managed Municipal ETF

Notizie

Ultime notizie per First Trust Managed Municipal ETF (NASDAQ:FMB)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO